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a b s t r a c t
Vaccine effectiveness (VE) studies provide a measure of population-based vaccine performance by com-
bining immunization history data with rates of disease incidence. This review assessed the feasibility of
using electronic immunization registry data sources in VE studies. Electronic databases were searched
through January 31, 2010. Out of 17 studies, only one paper assessed data accuracy (71%), and three
papers assessed population coverage of the registry (estimates ranged from 25% to 90%). This review
shows that registry-based data sources can be used to conduct VE studies in a variety of settings and
populations. However, we found little information regarding the quality of this data source in VE studies
and future evaluations should investigate their reliability, accuracy, and potential bias.
© 2010 Elsevier Ltd. All rights reserved.
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1. Introduction
In the United States, national recommendations provide guid-
ance for use of vaccines to reduce, eliminate, or eradicate 17
vaccine-preventable diseases. Recent reports indicate that the
number of cases of most vaccine-preventable diseases (VPD) is at
an all-time low. Hospitalizations and deaths attributable to VPD
have also decreased [1]. Other estimates indicate that vaccination
0264-410X/$ – see front matter © 2010 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2010.11.007
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with 7 of the 12 routinely recommended childhood vaccine pre-
vents an estimated 33,000 deaths and 14 million cases of disease
in every birth cohort, and saves society an additional $33 billion in
costs including disability and lost productivity [2].
However, despite their goal of providing safe, effective dis-
ease prevention, vaccines do not guarantee complete protection.
Recently published literature has re-examined epidemiological
concepts surrounding two study designs used to determine how
well a vaccine performs [3]. Pre-licensure, experimental vaccine
efﬁcacy trials represent how well the vaccine performs under
controlled conditions, and are best measured by double-blind,
randomized, clinical control trials [4]. This paper will focus on
population-based vaccine effectiveness (VE) studies. Evaluations of
VEoccur after vaccine efﬁcacyhas beenestablished, and assess how
well a vaccine performs under natural ﬁeld conditions rather than
in a controlled clinical trial. VE studies take into account vaccine
potency, how well target groups are immunized, and can control
for the complexities of immunization practices and transmission
dynamics such as exposure to disease, or individual response to
particular vaccines. Measures of VE can also assess the beneﬁts and
effects of a vaccination program or identify previously unknown
factors related to vaccine failure, and are critical to ensure that a
licensed vaccine is working within a population.
Several study designs can be used to evaluate VE: (1) retrospec-
tive case control studies compare vaccination rates among infected
cases and controls. This type of study expresses VE as a rate dif-
ference by calculating an odds ratio (OR) for developing infection
despite vaccination; (2) an indirect cohort study examines individ-
ual protective responses by comparing vaccine-serotype infection
rates with nonserotype-infection rates within a diseased popu-
lation [5]; (3) case-coverage studies compare vaccination rates
among cases with those of a similar cohort over a deﬁned period
of time, or (4) observational studies examine the change in disease
burden and impact of a vaccine within a population over time [3].
Observational studies are often designed to measure the impact of
a vaccine program by studying the effect of disease incidence in a
population before and after program implementation [6], and to
determine the relative risk of disease among the vaccinated groups
compared to the unvaccinated [7,8].
In the U.S., VE studies have utilized population-based data
by measuring immunization rates by telephone surveys, school-
andpractice-based assessments, and insurance claims information,
among others. These methods can be time-consuming, expensive,
and biased [9]. In response, an increasing number of resources,
including immunization registries,maintain immunization records
for infants, children, adolescents, and adults. These immuniza-
tion information systems (IISs) are repositories of immunization
data within speciﬁed geographic areas. IISs collect and consolidate
records of vaccinations from multiple health care providers and
across care settings. These surveillance systems have been shown
to provide better immunization delivery by assisting in medical
decision-making, reminder recall, determining coverage levels, and
identifying pockets of need [10–15]. IISs can be used in VE studies
tomeasure the degree of vaccine uptake in a variety of settings and
populations by identifying conﬁrmed VPD cases and/or conﬁrming
immunization history. Investigators then use this information to
calculate vaccine performance [16–19].
Using IIS data can offer several methodological advantages over
traditional observational studies. First, registries may allow more
rigorous researchmethods to be used: in population-based studies,
IISs provide individual-level information that can bematched with
VPDmorbidity data and could be used to conduct large cohort stud-
ies more efﬁciently. One beneﬁt of cohort studies is that they are
less prone to bias than case–control studies, a widely used design
in populations lacking registries. In case–control studies, IISs can
also provide a uniform method of determining vaccination status
for cases or controls, and can reduce bias due to differential ascer-
tainment of vaccination status. VE studies using IIS data can use
case–control or population-based study designs such as prospec-
tive or retrospective cohort, or cross-sectional study design. Since
registries contain population-based data for large numbers of peo-
ple, extracting immunization information from a registry means
that cohort studies could be conducted in populations with low
incidence of disease, or in other low-risk populations since there
is a larger sample from which to draw [20]. In addition, central-
ized data sources can allow researchers to measure the impact of
vaccination in populations precisely by deﬁning the base popula-
tion more clearly. This population-based approach can prevent the
introduction of socioeconomic or demographic biases that may be
present in other data sources such as HMO-based data [21].
There is also evidence that the use of registry-based data is
a developing ﬁeld. Many immunization registries are currently
operating all over the world. The US government, through CDC
goals of expanding registries and ﬁnancial incentives for fulﬁll-
ing meaningful use objectives for electronic health records (EHRs),
is instrumental in the promotion of IISs [22]. Furthermore, the
Health Information Technology for Economic and Clinical Health
Act (HITECH) Provisions within the ARRA were enacted in Febru-
ary 2009 [23]. As a result, there is an emphasis on improving
health information technology in the US, and an increasing number
of registries at state, city, and regional levels [12,24]. Centralized
statewide registries are currently operating in 48 of 50 states, as
well as several cities [21,25,26]. In one recent study, IIS data from
eight states and one city (representing approximately 10% of the
U.S. population) was used in the Post-Licensure Rapid Immuniza-
tion Safety Monitoring (PRISM) study identifying adverse events
from the H1N1 vaccine. PRISM represents a novel way of linking
IISs and heath plan data to assess population-based immunization
coverage and outcomes data on a nationwide basis.
However, considerable gaps exist in the literature detailing pre-
cisely howregistries can facilitatemore accurate, population-based
vaccine effectiveness studies. In addition, harnessing IISs is a new
and expanding ﬁeld, and methodological limitations such as miss-
ing, inaccurate, or the potential for biased data have not been
fully explored. Observational studies of vaccine effectiveness at the
population level depend on accurate data [27], and recent studies
have found that vaccination studies relying on electronic records
may misclassify vaccinated individuals as unvaccinated, thereby
producing inaccurate estimates of vaccine effectiveness [28]. This
systematic reviewwill determine how registries have been used to
conduct VE studies, and if data contained in the registry is accu-
rate and generalizable through the following aims: (1) to assess
if an individualized, centralized system for tracking immunization
rates can be utilized in vaccine effectiveness studies, (2) to describe
reported estimates and methods to measure accuracy of registry
data in VE studies, and (3) to describe reported results andmethods
tomeasure base population coverage of registry data in VE studies.
2. Methods
We conducted a systematic review of all availablemedical liter-
ature through January 31, 2010 that referred to or established the
useof registry-baseddata sources to evaluate vaccine effectiveness.
2.1. Search strategy
We searched the electronic databases PubMed, MedLine,
EMBASE, MeSH, ISI Web of Science, and the CDC immuniza-
tion information system (IIS) Database. The following terms
were used: ‘registry-based vaccine effectiveness’, or key words
‘immunization registry or register and vaccine effectiveness’;
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‘immunization information system and vaccine effectiveness’
(PubMed; MedLine; EMBASE); ‘vaccination registry’; or ‘cover-
age’; or ‘registries/standards’; or ‘registries/statistics andnumerical
data’; or ‘vaccination/statistics and numerical data’; or ‘immuniza-
tion programs/standards’; or ‘immunization programs/statistics
and numerical data’ (MeSH); ‘vaccin*; registr* and effective*’
(ISI Web of Science); and ‘vaccination registry’ (CDC IIS search).
This strategy was supplemented by searching the reference lists
of included articles to identify additional papers. Two authors
of included studies provided supplemental materials; and two
authors were contacted for recently published article content that
was not available during the initial search attempt.
2.2. Inclusion and exclusion criteria
Inclusion criteria were as follows: (1) researchers extracted
registry-based immunization data to conduct vaccine effective-
ness study in a human population; (2) study utilized any
population-based, centralized (national, statewide, countywide,
etc.) immunization registry data as a main source of vaccination
status information; and (3) studies were published in English.
Exclusion criteria were as follows: (1) review papers; (2) stud-
ies published in a language other than English; (3) studies that
included HMO-based or hospital-registry-based data only, with-
out population-based data; (4) studies that did not address vaccine
effectiveness; (5) studies with poor quality rating scores deﬁned as
<7 points out of a possible 14 points.
2.3. Deﬁnitions
‘Registry-based’ was deﬁned as any population-based data
source maintained at the local, regional, or national level
that systematically collects immunization history information.
Institutional- or HMO-based data did not meet review criteria in
this context. The ‘reference data source’ refers to a demographic,
census, or other population-based data source researchers used
to validate population-based registry data utilized in the study (if
applicable). ‘Population coverage estimates’ are the reported per-
centage of the source population included in the IIS. ‘Accuracy’
reported is the percentage of data that was consistent between the
registry information and a validatedmeasure (i.e. provider records,
parent recall, or manual validation). In addition, ‘VPD data sources’
are the data sources used to provide a measure of VPD to calculate
rates of vaccine effectiveness.
2.4. Data abstraction
We conducted a preliminary review by scanning article titles
and abstracts; papers were then retrieved, and study text was
scanned to determine if all inclusion criteria were met. To sys-
tematically collect data from included studies, we developed a
data abstraction form that was pilot-tested prior to data collection
(Appendix A).
2.5. Quality rating scores
AmodiﬁedDownsandBlackquality rating scalewasused to rate
the studies (Appendix B) [29].Wemodiﬁed some text of the check-
list and removedquestions related to randomized case–control and
intervention studies since these were not appropriate in this con-
text. We then abstracted data from the selected papers, rated the
studies independently, and comparedourquality rating scores.Dis-
crepancies in quality rating were discussed and addressed to reach
study quality consensus between reviewers.
2.6. Analyses
Wedetermined the number of studies using registry-based data
to conduct VE studies. We then determined the distribution of
rates for population coverage estimates, reported accuracy, and
described this range using descriptive statistics.
3. Results
3.1. Search results
Two hundred ninety-three papers were identiﬁed as fulﬁlling
the initial search criteria.
After application of the inclusion and exclusion criteria, 280 of
the studies were discarded (Fig. 1), and we included 13 articles
for ﬁnal review. The main reason for exclusion was that the study
did not use registry-based data to calculate VE (137 papers, 49% of
excluded studies). No studies were dropped because of poor study
quality.
Through direct systematic personal communication with
included authors, we obtained four additional papers and included
them in the ﬁnal review.
Table 1 describes basic characteristics of included articles. The
year of publication ranged from 1997 to 2010, and 13 of the 17
papers (76%) were published during or after 2004. Included studies
utilized four types of study design, and occurred in nine coun-
tries focusing on ten vaccine-preventable diseases. Registry types
includedcitywide, countywide, regional, statewide, andnational IIS
systems. Studies usedVPDdata collected fromhealthcareproviders
[30,31], linked notiﬁcation reports systems and hospital discharge
diagnosis data [32,33], or other national/regional disease surveil-
lance systems [34]. Information related to matching IIS data with
incident disease data at the individual-level is also included.
Table 2 contains information from the included studies high-
lighting speciﬁc IIS details. Results of themodiﬁedDowns andBlack
checklist to assess study quality indicate that out of a possible four-
teenpoints, all includedstudies scoredat least7points,withamean
study score of 11, and a range from 7 to 14 points. This table also
lists population-based data sources used for reference purposes,
study contexts, as well as accuracy and source population coverage
rates.
3.2. Use of registry data in VE studies
Reviewed VE studies demonstrated three unique contexts in
which registry-based data sources could identify immunization
history data:
1. Responding to an outbreak: Three studies responded to epidemi-
ological data showing an alarming increase in incidence for a
particular type of vaccine-preventable disease. These studies
used IIS-based data to identify outbreak cases and determine
immunization history of these cases. Studies were retrospective
in nature [30,31,35].
2. Assess how vaccination affects incidence of disease: Eight stud-
ies sought to measure the impact of vaccination programs by
comparing population-based immunization data with incident
rates of disease before and after implementation of vaccine
programs. Study results were reported as changes in rates of
incident disease as a result of implementation of vaccination
or another intervention. Studies were retrospective if authors
assessed or evaluated a vaccine program following its imple-
mentation [6,36–40]. One paper prospectively monitored the
impact of a vaccine intervention at the beginning of program
implementation [8].
Please cite this article in press as: Placzek H, Madoff LC. The use of immunization registry-based data in vaccine effectiveness studies. Vaccine
(2010), doi:10.1016/j.vaccine.2010.11.007
ARTICLE IN PRESSGModelJVAC-11121; No.of Pages13
4 H. Placzek, L.C. Madoff / Vaccine xxx (2010) xxx–xxx
Fig. 1. Flow chart of included and excluded articles.
3. Estimate vaccine effectiveness for a speciﬁc vaccine using
population-based data: Six studies monitored how effectively
vaccines could prevent VPD. Of these, two studiesmatched cases
with controls to conduct case–control evaluations of VE [41,42].
Three studies utilized a population-based data source to calcu-
late risks of infection in vaccinated compared to unvaccinated
groups, and expressed VE as an odds ratio (OR) [19,33,34]. One
paper conducted serological testing of possible inﬂuenza cases,
and compared vaccination rates between laboratory-conﬁrmed
and -unconﬁrmed cases [12]. In these studies, authors calculated
VE by comparing immunization history data with incident cases
of disease.
3.3. Accuracy in IISs
Only one of the 17 papers (6%) addressed accuracy of informa-
tion contained in the IIS (Table 2). In this study, researchers found
65–77% accuracy of IIS data.
In this instance, Boom et al. assessed the effectiveness of pen-
tavalent rotavirus vaccine (RV5). They also sought to validate
immunization data from the Houston-Harris County Immuniza-
tion Registry (HHCIR) against provider records to assess the utility
of an IIS in evaluating VE. Results showed that registry data were
the same as the provider record for 71% of patients. These authors
also found that VE calculated using IIS data (VE for RV5 was 89%
[CI]:70–96% and 85% [CI]:55–95%) was similar to estimates using a
manually validated control group based on provider records (82%
[CI]: 19–96%) [42].
3.4. Population coverage in IISs
While there are different methods of comparing or deﬁning a
base population, of the 17papers included in this review, only three
(18%) reported how many of the source population were included
in the registry. Population coverage estimates encompassed awide
range of target population coverage estimates ranging from 25% to
90%.
For example, Fu et al. determined the effectiveness of the
mumps vaccine against clinical mumps in outbreak cases. Cases
were identiﬁed from physician-based surveillance data, and only
cases whose information was found in the IIS were included in the
study. Of the 1849 children in Guangzhou identiﬁed with mumps
between Sept 1, 2004 andMarch 31, 2005, 1380 (74.6% of the total)
were excluded because their records were not found in the system
[35].
4. Discussion
This review shows that registry-based data have been used to
evaluate VE in a variety of settings, contexts, and populations.
We have found studies that matched registry-based immuniza-
tion history data and measures of incident disease to assess VE
in population-based settings. In order for IISs to provide accurate
calculations of VE, however, twomajor assumptions should be sat-
isﬁed:
Assumption 1: Data contained in the IIS accurately report who has
or has not received a vaccine. This assumes that all IIS information is
correct, and requires validation of accuracy, or matching of infor-
mation from a reference data source. In this review, some papers
indicated a need for establishing more accurate data, but did not
conduct data validation [36]. Authors also noted that their registry
data source might have underestimated current coverage due to
incomplete reporting of vaccination status which may cause an
underestimation of VE [19].
Assumption 2: Immunization data contained in the registry are rep-
resentative of the general population. This assumes that the IIS in
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Table 1
Basic characteristics of articles included in the review (n=17).
First author Title Year Study design Vaccine type Sample size Study setting IIS type VPD data source IIS data matched to
individual-levela
1 Van Alphen Effect of nationwide vaccination of
3-month-old infants in the Netherlands with
conjugate Haemophilus inﬂuenzae type b
vaccine: high efﬁcacy and lack of herd
immunity
1997 Case–control Haemophilus
inﬂuenzae type b
1.6 million Netherlands National National Reference Lab for
Bacterial Meningitis
Yes
2 Anonymous Measles outbreak – Netherlands, April
1999–January 2000
2000 Retrospective
cohort
Measles 2,907 Netherlands National National routine
surveillance data
Yes
3 Markey The effectiveness of Haemophilus inﬂuenzae
type b conjugate vaccines in a high risk
population measured using immunization
register data
2001 Retrospective
cohort
Haemophilus
inﬂuenzae type b
119 Australia National Regional Hospital
laboratory/Infection
Control data
N/A
4 Averhoff Control of hepatitis A through routine
vaccination of children
2001 Prospective cohort Inactivated
hepatitis A
29,789 US: Butte County,
CA
Countywide Enhanced regional
surveillance
Yes
5 Torvaldsen Effectiveness of pertussis vaccination in New
South Wales, Australia 1996–1998
2003 Retrospective
cohort
Pertussis 1,278 South Wales,
Australia
National Notiﬁable Diseases
Database of the NSW DoH
Yes
6 Hviid Impact of routine vaccination with a conjugate
Haemophilus inﬂuenzae type b vaccine
2004 Retrospective
cohort
Haemophilus
inﬂuenzae type b
758,988 Denmark National National Hospital
Discharge Registry
Yes
7 Hviid Impact of routine vaccination with a pertussis
toxoid vaccine in Denmark
2004 Retrospective
cohort
Pertussis 541,525 Denmark National National Hospital
Discharge Registry and
national reporting data
Yes
8 Barricarte Effectiveness of the 7-valent pneumococcal
conjugate vaccine: a population-based
case–control study
2007 Case–control 7-valent
pneumococcal
conjugate (PCV7)
510 Navarra, Spain Regional Regional hospital
laboratory data
Yes
9 Kelly A Prospective Study of the Effectiveness of the
New Zealand meningococcal B vaccine
2007 Prospective cohort Meningococcal B 1,190 New Zealand National National surveillance
(EpiSurv) combined with
lab data
Yes
10 Ortqvist Inﬂuenza vaccination and mortality:
prospective cohort study of the elderly in a
large geographical area
2007 Prospective cohort Trivalent
split-virion
inﬂuenza
260,000 Stockholm County,
Sweden
National Weekly surveillance,
Swedish Institute for
Infectious Disease Control
Yes
11 Fu Matched case–control study of effectiveness of
live, attenuated S79 mumps virus vaccine
against clinical mumps
2008 Case–control Live, attenuated
S79 mumps virus
938 Guangzhou, China Citywide Guangzhou Center for
Disease Control and
Prevention (Guangzhou
CDC)
Yes
12 Anonymous Interim within-season estimate of the
effectiveness of trivalent inactivated inﬂuenza
vaccine-Marshﬁeld, WI 2007–2008 inﬂuenza
season
2008 Case–control Trivalent
inactivated
inﬂuenza
616 US: Marshﬁeld, WI Regional Regional/statewide
laboratory data
Yes
13 Adamkiewicz Effectiveness of the 7-valent pneumococcal
vaccine in children with sickle cell disease in
the ﬁrst decade of life
2008 Retrospective
cohort
7-valent
pneumococcal
conjugate (PCV7)
1,247 US: Metro Atlanta,
GA
Regional Pop-based surveillance
from Georgia Emerging
Infections Program (EIP)
Yes
14 Bialek Impact of routine hepatitis B immunization on
the prevalence of Chronic hepatitis B virus
infection in the Marshall Islands and the
Federated States of Micronesia
2009 Retrospective
cohort
Hepatitis B 1,171 Micronesia National Laboratory conﬁrmation
from serosurvey samples
N/A
15 Fu Evaluation of live attenuated S79 mumps
vaccine effectiveness in mumps outbreaks: a
matched case–control study
2009 Case–control Live, attenuated
S79 mumps virus
388 Guangzhou, China Citywide Guangzhou Center for
Disease Control and
Prevention (Guangzhou
CDC)
Yes
16 Galloway Use of an observational cohort study to
estimate the effectiveness of the New Zealand
group B meningococcal vaccine in children
2009 Retrospective
cohort
Meningococcal B 258,421 New Zealand National Surveillance data from
Institute of Environmental
Science & Research
Yes
17 Boom Effectiveness of pentavalent rotavirus vaccine
in a large urban population in the United States
2010 Cross-sectional Pentavalent
rotavirus (RV5)
285 US: Houston-Harris
County, TX
Countywide Surveillance data, Texas
Children’s Hospital
Yes
a ‘N/A’ indicates VPD data not matched to individual-level IIS data.
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Table 2
Key IIS components and study characteristics.
First author Year Quality rating Study context Accuracy
reporteda
Reference
population-based
data source
Source population
coverageb
1 Van Alphen 1997 10 Monitor incidence
of disease
N/A Central Bureau of
Statistics
N/A
2 Anonymous 2000 7 Responding to an
outbreak
N/A N/A N/A
3 Markey 2001 13 Monitor incidence
of disease
N/A Australian Bureau
of Statistics
90%
4 Averhoff 2001 12 Monitor incidence
of disease
N/A State of CA, Dept. of
Finance,
Demographic
Research Unit
N/A
5 Torvaldsen 2003 14 VE N/A N/A N/A
6 Hviid 2004 12 Monitor incidence
of disease
N/A Central
Registration
System
N/A
7 Hviid 2004 14 Monitor incidence
of disease
N/A Danish Civil
Registration
System
N/A
8 Barricarte 2007 11 VE N/A N/A N/A
9 Kelly 2007 13 Monitor incidence
of disease
N/A Statistics New
Zealand
N/A
10 Ortqvist 2007 13 VE N/A Stockholm County
Population Register
N/A
11 Fu 2008 11 Responding to an
outbreak
N/A N/A 25.4%
12 Anonymous 2008 9 VE N/A N/A N/A
13 Adamkiewicz 2008 10 Monitor incidence
of disease
N/A National
Immunization
Survey
N/A
14 Bialek 2009 7 Monitor incidence
of disease
N/A N/A N/A
15 Fu 2009 11 Responding to an
outbreak
N/A N/A N/A
16 Galloway 2009 12 VE N/A Statistics New
Zealand
N/A
17 Boom 2010 13 VE 71% N/A 44%
a ‘N/A’ indicates no reported measure of accuracy in study results.
b ‘N/A’ indicates no reported measure of source population coverage in study results.
question is representative of the entire denominator of the source
population, and requires validation by comparing IIS data to census
results or other population-based data sources.
In countries that have linked census, healthcare utilization, and
health outcomedata, conﬁrmingpopulation coverage ismoreman-
ageable, for example, by using a unique identiﬁcation number to
link all national registries [33,38]. However, in countries without
integrated national registries, there are no centralized linked sta-
tistical bureauswith demographic, healthcare, and utilization data.
Without linkage capabilities, it can be challenging to conduct large
population-based VE studies. Reference population data used in
U.S. studies included National Immunization Survey data [8], or
census data from the State of California [6]. These data sources can
be limited by low participation rates and selection bias, and may
not provide individual-level information.
Individual-level IIS data provide the level of detail required to
conduct rigorous VE studies [43], and most population-based VE
studies included in this reviewprovideVPD incidencedata linked to
individual-level immunization data. However, some authors noted
that, because of poor quality registry data, precise rates of vaccine
coverage could not be determined [6,36], and two studies calcu-
late VE based on aggregate coverage and/or disease levels. In one
paper, authors indicated that poor quality IIS data could not be
used to calculate immunization history, therefore mean vaccine
coverage statistics were used to determine the denominators for
VE calculations, rather than using IIS data directly [36]. Another
study used IIS data to generate vaccination rates for the popula-
tion, but applied these rates tomean disease levels to conclude that
implementation of vaccination had decreased incidence of disease
[37].
4.1. Conclusions
This is the ﬁrst systematic review that has assessed the use of
registry-baseddata invaccineeffectiveness studies. This reviewhas
shown that central immunization registries can be useful tools for
evaluating the impact of immunization programs bymeasuring VE
as a response and preventive measure in a variety of populations,
study contexts, anddiseases. It alsodemonstrates thepotential util-
ity of an immunization registry to conduct future VE studies and
highlights future potential applications of registry-based data.
However, this review found that the quality of information
may vary between registries, and much work remains to be done
validating the accuracy and precision of immunization registry
information. Standards and regulations do exist on issues sur-
rounding costs, access and provider matters, validation methods,
technical design considerations, and legal environment [12]. It is
also true that other literature has addressed accuracy and gener-
alizability of registry-based data [20,44,45], which indicates that
validation methods for registry-based data have been developed
and tested. In this review, only one study assessed accuracy of IIS
data, and three papers assessed source population coverage rates.
Because of the limited information available, IIS data quality, inher-
ent bias, and population coverage can be difﬁcult to assess, and
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drawing conclusions about the impact of validation techniques is
difﬁcult.
Studies also deﬁned the base population differently, or had
limited access to the base population information due to techno-
logical or ﬁnancial limitations. Thus, even if consistent validation
methods have been deﬁned and tested elsewhere, technological or
ﬁnancial limitations can be considerable, and researchers may not
have the resources to apply consistent validationmeasures in their
studies.
In addition, reliable estimates of VE depend on accurate
measures of disease incidence data, and require validated meth-
ods to match disease and immunization history data at the
individual-level. This review did not assess the quality of inci-
dent disease data, but this should be addressed in future
work.
Finally, improvements in the quality of individual-level immu-
nization history data would strengthen VE studies using IISs by
providing more precise information about who has or has not
received a particular vaccine during a speciﬁed time period. These
data could allow researchers to understand responses to current
vaccines and better prepare for future pandemics. Higher qual-
ity individual-level data could also help us monitor the impact
of the change of vaccines as well as shifts in VE attributable to
other factors such as shifts in prevalent strains of pathogens, or
herd immunity in the general population. Responding to today’s
changing and emerging vaccine-preventable diseases, more atten-
tion must be paid to the development of registry-based data
sources to conduct population-based vaccine effectiveness stud-
ies.
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Appendix A. Abstraction form for a systematic review: immunization registry data as a method of surveillance in a pediatric
population
Number of the study:
Study title: 
First author of the study: 
Year of publication: 
1. Inclusion and Exclusion Criteria:
Is the study being included? 
1. Yes
2. No
2. Reason(s) for inclusion/exclusion (check the following items that apply from the inclusion 
and exclusion criteria): Inclusion Criteria:
1. Focus of the study is vaccine effectiveness in a specified population 
2. Study utilizes any population-based, centralized (statewide or citywide) immunization 
registry data as a main source of vaccination status information
3. Studies were published in English.
3. Exclusion criteria:
1. Review papers
2. Study does not include population-based registry-based data.
3. Study does not focus on vaccine effectiveness.
4. Studies published in language other than English
5. Studies have poor quality rating score
Reference: 
Study type:
a. Clinical trial 
b. Observational study
c. Cohort: prospective or retrospective
d. Case−control
e. Cross-sectional
f. Survey
g. Other
4. Background/study aims:
5. Study objectives:
6. Study population: 
a. Inclusion criteria:
b. Exclusion criteria:
c. Sample size: Total: Male: Female:
d. Mean age ± SD or CI:
e. Age groups:
f. Gender distribution: Male(%): Female(%):
g. Control or comparison groups, if applicable: Yes No
h. SES Information available:
i. Race/ethnicity information
j. Other immunization/anti-viral hx information:
7. Study setting: 
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Study location: - Urban - Rural  - Mixed
8. Assessment of exposure:
- Registry (is self-report included?) How is immunization status determined?
- Method of validation?
9. Assessment of outcome:
How was timing of disease season determined?
How is VE calculated/defined? 
How is VE measured?
10. Study time period:
11. IIS Specifics:
• What is specific role of IIS in this study?
• What type of data is contained in the immunization information system (IIS)?
• Is there an indication of accuracy?
• How is the registry system organized and maintained? Who funds this system?
• Was a reference data source used to assess the source population coverage?
• Is this a cross-sectional estimate, or conducted over a period of time?
ο Is there a method of tracking immunization rates in order to compare annual 
rates?
• How is the registry tied into public health efforts?
• Other?
ο Is there evidence of increased immunization/utilization among target 
populations?
ο Address size of target and enrolled populations: high-risk groups, SES, race-
ethnicity
12. Results: 
Is a change in disease incidence reported?
Are figures reported for VE? If so, list them here:
13. Study design characteristics:
Types of bias addressed:
- Selection
- Detection
- Report
- Attrition
- Other
Residual confounding addressed?
Confounders:
a. Adjusted for potential confounders:
i. Yes
ii. No
b. List of confounders:
14. Appropriate statistical analysis?
15. Limitations:
16. Main findings:
17. Other notes:
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Appendix B. MODIFIED Downs and Black checklist
Reporting
Total: 
1. Is the hypothesis/aim/objective of the study clearly described?
Yes 1
No 0
2. Are the main outcomes to be measured clearly described in the Introduction or 
Methods section?
If the main outcomes are first mentioned in the Results section, the question should be 
answered no.
Yes 1
No 0
3. Are the characteristics of the patients included in the study clearly described? In cohort 
studies and trials, inclusion and/or exclusion criteria should be given. In case-control 
studies, a case-definition and the source for controls should be given.
Yes 1
No 0
4. Are the interventions of interest clearly described? Treatments and placebo (where 
relevant) that are to be compared should be clearly described.
Yes 1
No 0
5. Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? A list of principal confounders is provided.
Yes 2
Partially 1
No 0
6. Are the main findings of the study clearly described? Simple outcome data (including 
denominators and numerators) should be reported for all major findings so that the reader 
can check the major analyses and conclusions (This question does not cover statistical 
tests which are considered below).
Yes 1
No 0
7. Does the study provide estimates of the random variability in the data for the main 
outcomes? In non normally distributed data the inter-quartile range of results should be 
reported. In normally distributed data the standard error, standard deviation or confidence 
intervals should be reported. If the distribution of the data is not described, it must be 
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assumed that the estimates used were appropriate and the question should be answered 
yes.
Yes 1
No 0
8. Have actual probability values been reported (e.g. 0.035 instead of 0.05) for the main 
outcomes except where the probability value is less than 0.001?
Yes 1
No 0
External validity
All the following criteria attempt to address the representativeness of the findings of the study 
and whether they may be generalized to the population from which the study subjects were 
derived.
9. Were the subjects asked to participate in the study representative of the entire 
population from which they were recruited? The study must identify the source 
population for patients and describe how the patients were selected. Patients would be 
representative if they comprised the entire source population, an unselected sample of 
consecutive patients, or a random sample. Random sampling is only feasible where a list 
of all members of the relevant population exists. Where a study does not report the 
proportion of the source population from which the patients are derived, the question 
should be answered as unable to determine.
Yes 1
No 0
Unable to determine 0
10. Were the staff, places, and facilities where the patients were treated, representative of 
the treatment of the majority of patients receive? If yes, the study should demonstrate 
that the intervention was representative of that in use in the source population. The 
answer should be no if the intervention was undertaken in a specialist center 
unrepresentative of the hospitals most of the source population would attend.
Yes 1
No 0
Unable to determine 0
Internal validity – bias
11. Were the statistical tests used to assess the main outcomes appropriate? The statistical 
techniques used must be appropriate to the data. For example nonparametric methods 
should be used for small sample sizes. Where little statistical analysis has been 
undertaken but where there is no evidence of bias, the question should be answered yes. 
If the distribution of the data (normal or not) is not described it must be assumed that the 
estimates used were appropriate and the question should be answered yes.
Yes 1
No 0
Unable to determine 0
12. Were the main outcome measures used accurate (valid and reliable)? For studies where 
the outcome measures are clearly described, the question should be answered yes. For 
studies which refer to other work or that demonstrate the outcome measures are accurate, 
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the question should be answered as yes.
Yes 1
No 0
Unable to determine 0
13. Was there adequate adjustment for confounding in the analyses from which the main 
findings were drawn? This question should be answered no for trials if: the main 
conclusions of the study were based on analyses of treatment rather than intention to 
treat; the distribution of known confounders in the different treatment groups was not 
described; or the distribution of known confounders differed between the treatment 
groups but was not taken into account in the analyses. In nonrandomized studies if the 
effect of the main confounders was not investigated or confounding was demonstrated 
but no adjustment was made in the final analyses the question should be answered as no.
Yes 1
No 0
Unable to determine 0
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